PYC Therapeutics Stock Value
PYC Therapeutics Company Info
EPS Growth 5Y
-216,23%
Market Cap
$1,16 B
Long-Term Debt
$0,00 B
Quarterly earnings
05/28/2026 (E)
Dividend
$0,00
Dividend Yield
0,00%
Founded
2001
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
$3,88
228.81%
Last Update: 04/11/2026
Analysts: 5
Highest Price Target $5,00
Average Price Target $3,88
Lowest Price Target $2,30
In the last five quarters, PYC Therapeutics’s Price Target has risen from $0,25 to $0,30 - a 20,00% increase. Two analysts predict that PYC Therapeutics’s share price will increase in the coming year, reaching $3,88. This would represent an increase of 228,81%.
Top growth stocks in the health care sector (5Y.)
What does PYC Therapeutics do?
PYC Therapeutics Limited, a drug-development company, focuses on the discovery and development of novel RNA therapeutics aimed at treating genetic diseases. The company operates in a specialized sector that leverages advancements in RNA technology to develop therapeutic solutions for unmet medical needs.
Business Segments
The company comprises a single business segment dedicated to the discovery and development of innovative RNA therapeutics. The primary operational location is in Australia, c...
PYC Therapeutics Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Industry Revenues:**
- Biotechnology: 100% (2026)
**TOP 3 Markets:**
- Australia: 40%
- USA: 35%
- Europe: 25%
PYC Therapeutics Limited is a company specializing in the development of biotechnology solutions, particularly in the field of RNA-based therapies. The company's revenues...
At which locations are the company’s products manufactured?
**Production Site:** Perth, Australia (As of 2023)
PYC Therapeutics Limited, a biopharmaceutical company, is headquartered and has its production facility in Perth, Australia. The company focuses on the development of RNA-based therapeutics. The location in Perth enables PYC to benefit from proximi...
What strategy does PYC Therapeutics pursue for future growth?
**Focus on RNA Therapies:** PYC Therapeutics is focusing on the development of RNA-based therapies, particularly for the treatment of genetic diseases.
**Partnerships and Collaborations:** The company relies on strategic partnerships with other biotech and pharmaceutical companies to accelerate its...
Which raw materials are imported and from which countries?
I'm sorry, but I do not have specific data on the commodities or materials that PYC Therapeutics Limited imports, nor from which countries they originate.
In general, it can be said that biopharmaceutical companies like PYC Therapeutics often rely on a variety of raw materials, including chemi...
How strong is the company’s competitive advantage?
**Competitive Advantage:** Moderate to Strong (estimated 2026)
PYC Therapeutics Limited, a company in the biotechnology sector, specializes in the development of RNA-based therapeutics. The company's competitive advantage lies primarily in its innovative platform technology, which enables the...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 45% (estimated for 2026)
**Insider Buys/Sells:** No current data available (as of 2026)
The institutional investor share in PYC Therapeutics Limited is estimated to be around 45%. This indicates a moderate interest from institutional investors, which could suggest...
What percentage market share does PYC Therapeutics have?
**Market share of PYC Therapeutics Limited:** Estimated 2-3% (2026)
**Top competitors and their market shares:**
1. **Ionis Pharmaceuticals:** 15%
2. **Alnylam Pharmaceuticals:** 12%
3. **Moderna, Inc.:** 10%
4. **BioNTech SE:** 9%
5. **Arrowhead Pharmaceuticals:** 7%
6. **Sarepta Therapeutics:** 6...
Is PYC Therapeutics stock currently a good investment?
**Revenue Growth:** 18% (2025)
**Research and Development Expenses:** 45% of Revenue (2025)
**Partnerships:** New strategic alliance with a leading pharmaceutical company (2025)
PYC Therapeutics Limited achieved a revenue growth of 18% in 2025, attributed to the successful development and commercia...
Does PYC Therapeutics pay a dividend – and how reliable is the payout?
**Dividend payment:** None (as of 2026)
PYC Therapeutics Limited has not distributed any dividends to its shareholders so far. The company is in a growth and development phase where it primarily invests its resources in research and development. This is typical for biotechnology companies focusing...
